FDA head Gottlieb criticizes industry for ‘Kabuki drug-pricing’

WASHINGTON (Reuters) – U.S. Food and Drug Administrator Scott Gottlieb on Wednesday criticized drugmakers, pharmacy benefit managers and health insurers for “Kabuki drug-pricing constructs” that he said expose consumers to high out-of-pocket costs and discourage competition.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply